¼ÓÈëVIP ÉÏ´«¿¼²©×ÊÁÏ ÄúµÄÁ÷Á¿ Ôö¼ÓÁ÷Á¿ ¿¼²©±¨°à ÿÈÕÇ©µ½
   
Ö÷Ìâ : µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ
¼¶±ð: ³õ¼¶²©ÓÑ
ÏÔʾÓû§ÐÅÏ¢ 
Â¥Ö÷  ·¢±íÓÚ: 2007-04-19   

µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ

µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ ѧ¿Æ×¨Òµ£º ic}TiTK  
2aR9vmR  
´«È¾²¡Ñ§ ¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ dYOY8r/  
mc`Z;D/mt  
Ò». Ãû´Ê½âÊÍ(ÿÌâ4·Ö,¹²32·Ö) RIUJX{?  
I%:?f{\  
1. ICAM-1 ->OVNmCB`+  
%hmRh~/&  
2. interleukin 12(IL-12) &'zc2  
]iW:YNvXA  
3. tumor infiltrating lymphocyte pdFO!A_t  
'Qg!ww7O  
4. TCR/CD3 complex MBj Ae!,-  
V= &M\58  
5. hematopoietin receptor family [f { qb\  
=rZ'!Pa  
6. individual idiotype(IdI) !#%>,X#+  
~s-gnp  
7. integrin N)D+FV29y  
KkTE -$-  
8. colony-stimulatory factor (CSF) #Vmf 6  
~ a4Y8r  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© qAd=i0{N  
?Bq^#i |m  
1. ÃâÒßÇòµ°°×ÖØÁ´µÄ»ùÒòÈçºÎ½øÐÐÀà±ðת»»(class switching )? zjow %  
?%~^PHgZ|  
2. ¼òÊöɱÉËÐÔTϸ°û(Tc)ɱÉ˲¡¶¾¸ÐȾ°Ðϸ°ûµÄ»úÀí¡£ a}FY^4hl+  
JF~9efWe>  
3. ÉúÎïÓ¦´ðµ÷½Ú¼Á( biological response modifier,BRM)Ö÷ÒªÓÐÄļ¸Àà?¼òÒª½éÉÜÔÚ´«È¾ÐÔ¼²²¡·ÀÖÎÖеÄ×÷Óᣠoj{CNa  
!"yr;t>|Zb  
4. ¼òÊö¿¹Ô­Ìá³Êϸ°û(APC)Ó븨ÖúÐÔTϸ°û(Th)Ï໥×÷ÓõĹØÏµ¡£ PCL ;Z  
l(87s^_  
Èý. ÎÊ´ðÌâ(ÿÌâ18·Ö,¹²36·Ö) - G/qfd|s/  
t_!p({  
1. ÊÔÊö¸ÉÈÅËØµÄ·ÖÀ༰ÆäÉúÎïѧ×÷ÓÃÌØµã¡£Ö÷Òª¿ÉÒÔÖÎÁÆÄÄЩ´«È¾ÐÔ¼²²¡?¼òÊö¸ÉÈÅËØ¼ì²âµÄ·½·¨ºÍÔ­Àí¡£ U$OI]Dd9  
_#r00Ze  
2. ºÎΪ»ùÒò¹¤³Ì¿¹Ìå?Ŀǰ¹úÄÚÍâÔÚ»ùÒò¹¤³Ì¿¹ÌåÑо¿ÖÐÓÐÄÄЩÖ÷Òª½øÕ¹? µÚËľüÒ½´óѧһ¾Å¾ÅÈýÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ѧ¿Æ×¨Òµ: ´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© 1. CD4 2. T cell receptor(TCR) f@hM^%  
,YvOk|@R  
3. immunoglobulin superfamily (IgSF) _A!Fp0}`  
O<V 4j,  
4. selectin }Md;=_TP  
*{+{h;p  
5. anti-idiotypic antibody (¦ÁId) Mh~}RA"H  
?$ )5NQB%  
6. major histocompatibility complex(MHC) a,S;JF)v  
d,l?{ Ln  
7. immunotolerance ]OdZlZBsJ  
N2'aC} I  
8. biological reponse modifier(BRM) P][jB  
cXqYO|3/M  
9. immune reponse gene (Ir gene) CKK}Z;~:  
:[_ms d  
10. reshaped antibody (or reconstituted antibody) @ G)yz!H  
U3V5Jo r#  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© zX&SnT1~  
I@9'd$YY  
1. ¼òÊö°×ϸ°û½éËØ6(IL-6)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¡£ m:?"|. ]  
3)W zX  
2. ϸ°û¶¾ÐÔTÁܰÍϸ°û(Tc»òCTL)Ó뿹ÌåÒÀÀµµÄϸ°û½éµ¼µÄϸ°û¶¾(ADCC)ɱÉË»úÀíÓкβ»Í¬? b@;Wh-{d  
k[ro[E  
3. ¼òÊöµÚ¢ôÐÍ(³Ù·¢ÐÍ)±ä̬·´Ó¦µÄ·¢Éú»úÀí¡£ W/ Q*NB  
DpgTm&}-  
4. NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄ±íÃæ±ê¼Ç?NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄÉúÎïѧ»îÐÔ? R03 Te gwA  
@GFB{ ;=  
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö) ¹©´«È¾²¡Ñ§×¨ÒµÊÔÌ⣺ pqfX}x  
}LT&BNZj  
1. »úÌåÓÐÄÄЩÃâÒßϸ°ûºÍÃâÒß·Ö×Ó²ÎÓ뿹²¡¶¾¸ÐȾ?ËüÃÇÊÇÈçºÎ·¢»Ó²¡¶¾ÃâÒß×÷ÓõÄ? A<X?1$  
aE`d[d SG  
2. Ŀǰµ¥¿Ë¡¿¹ÌåÔÚ²¡¶¾Ñ§ÖÐÓÐÄÄЩÖ÷ÒªÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? ¡¡ Q< :RLKVT  
RPW46l34  
¹©Ïû»¯ÄÚ¿Æ×¨ÒµÊÔÌ⣺ =+!l8o&o,  
K] (*l"'U5  
1. ĿǰÌåÄÚºÍÌåÍâ¼ì²âÖ×Áö»¼ÕßÃâÒß¹¦Äܵķ½·¨Ö÷ÒªÓÐÄÄЩ?·Ö±ðÐðÊöÿÖÖ·½·¨µÄÔ­ÀíºÍ½á¹û²â¶¨? cgMF?;V  
a]T:wUYG'  
2. Ŀǰµ¥¿Ë¡¿¹ÌåÔÚÖ×ÁöѧÖÐÓÐÄÄЩÖ÷ÒªµÄÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? ¡¡ Oo|PZ_P  
pUXoSnIq:  
µÚËľüÒ½´óѧһ¾Å¾ÅËÄÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ѧ¿Æ×¨Òµ: gYB!KM *v  
 }~/b%^  
´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿: X/,) KTo7  
aj1]ZT \  
ÃâÒßѧ 4 O!2nP  
N ,Eap K G  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© +i&<`ov  
J-v1"7[2GC  
1. CD8 <+QQiFj  
b6N[t _,  
2. T cell receptor ¦Á and ¦Â chain (TCR¦Á¦Â ) ??,[- Oi  
GJeG7xtJKl  
3. immunoglobulin fold(Ig fold) I=y7$+7%  
Jb QK$[z"  
4. cadherin (Ca-dependent cell adhesion moleculers) r)*23&Ojs  
lG7PM^Eb  
5. idiotype-anti-idiotypic antibody immune network theory {zwH3)|Hn  
4)S99|1  
6. HLA class II antigen NKu[6J?)  
>'*%wf[{  
7. complementarity-determining region (CDR) -s3`mc}*  
s1:Wrz?4  
8. perforin(or pore-forming protein ,PFP) 8xPt1Sotq[  
e4S@ J/D  
9. high affinity IL-2 receptor \^!;r9z=A  
5\+*ml  
10. artificial active immunization >,e^}K}C  
nip6|dN  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© azPH~' E'  
K:,V>DL  
1. ¼òÊö°×ϸ°û½éËØ2(IL-2)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¼°ÆäÔÚÁÙ´²ÖÎÁÆÖеÄÓ¦Óᣠ"q=Cye  
pbH!u+DF  
2. Çë±È½ÏµÚ¢ñÐÍ(ËÙ·¢ÐÍ)³¬Ãô·´Ó¦ÓëµÚ¢ôÐÍ(³Ù·¢ÐÍ)³¬Ãô·´Ó¦µÄ·¢²¡Ìص㡣 ?qgQ)#6  
%K6veB{M  
3. ÊÔÊö·ÖÃÚÐÍIgA(secretory IgA)µÄ½á¹¹ÌصãºÍºÏ³É·ÖÃÚ¹ý³Ì¡£ &jE\D^>ko  
Cv**iW  
4. ÊԱȽÏT¡¢BÁܰÍϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(Èç±íÃæ¿¹Ô­¡¢±íÃæÊÜÌåµÈ)µÄÒìͬµã¡£ BEDkyz;:  
u{sHuVl  
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö¡£Çë×¢Ò⣺ÿλ¿¼ÉúÖ»ÄÜ´Ó1¡¢2ÌâÖÐѡһÌâ,3¡¢4ÌâÖÐѡһÌâ,¹²´ðÁ½Ìâ,¶à´ðÕß²»¼Æ·Ö¡£) 1. Ŀǰ¼ì²âϸ°ûÒò×ÓÖ÷ÒªÓÐÉúÎïѧ»îÐÔ¼ì²â·¨ºÍÃâÒßѧ¼ì²â·¨,Çë¾ÙÀý·Ö±ðÐðÊöÁ½ÖÖ·½·¨µÄʵÑéÔ­Àí¡£ 4ud(5m;Rle  
8y LcTA$T  
2. ΪÁ˱ÜÃâIgG¿¹ÌåFc¶Î·ÇÌØÒìÐÔ×÷ÓÃ,³£Ó¦ÓÃθµ°°×øˮ½âµÄF(ab¡¯)2¶Î,ÊÔÎÊÈçºÎÓ¦ÓÃSDS-PAGE·½·¨¶ÔF(ab¡¯)2½øÐмø¶¨? y]db]pP5  
l_g$6\&|  
3. ÊÔÊö¿¹Ö×Áö»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ M\]lNQA  
PLCm\Oh$l  
4. ÊÔÊö¿¹²¡¶¾»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ ¡¡ ? i{?Q,  
.5|[gBK  
µÚËľüÒ½´óѧһ¾Å¾ÅÎåÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ I\l&'Q^0@  
on_h'?2  
ѧ¿Æ×¨Òµ£ºÃâÒßѧ¡¢´«È¾²¡Ñ§¡¢Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿£ºÃâÒßѧ r2-iISxg+  
E'08'8y  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© yE:y[k0E  
2j s/>L0  
1. immunoglobulin gene rearrangement ynI e4b  
]LvP)0=  
2. the common chain of cytokine receptor (or a cytokine receptor subunit shared by some cytokine receptors) yGa0/o18!?  
cMT7Bd  
3. flow cytometry(FCM) S;~eI8gQ"  
)N.3Q1g-  
4. carrier effect .p[uIRd`  
K9N31'  
5. positive selection of T lymphocytes in thymus *!QmYH5r0  
#V k?  
6. mouse TH1(Th1) and TH2(Th2) subsets *AH `ob}  
*zdD4 I=  
7. perforin (pore-forming protein ,PFP) ^/n1h g  
<"3q5ic/Z  
8. ADCC(antibody-dependent cell-mediated cytotoxicity) UC`h o%OBF  
EyK!'9~a  
9. SH-2(src-homology region 2) T+Yv5l  
A/y|pg5  
10. Ab2¦Â (internal image) w%L4O;E]*{  
A7L;ims7  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© ^G!cv  
xp|1yud  
1. ½üÄêÀ´ÔÚÈËÀà°×ϸ°û·Ö»¯¿¹Ô­(CD)Ñо¿ÁìÓòÖÐÓÐÄÄЩÖ÷Òª½øÕ¹? @X/ 1`Mp  
3zsp 6kV  
2. ²ÎÓë»î»¯Tϸ°ûÓë»î»¯Bϸ°ûÏ໥×÷ÓõķÖ×ÓÖ÷ÒªÓÐÄÄЩ?¼òÊöÆä½á¹¹ºÍ¹¦ÄÜ? OY1bFIE  
]xRR/S4  
3. ÊÔÊöHLAÔÚÁÙ´²ÉϵÄÖ÷ÒªÓ¦Óᣠe66Ag}Sw|  
ip?]&5s  
4. Àý¾ÙÈýÖÖ´ÓÈËÍâÖÜѪµ¥¸öºËϸ°û(PBMC)Öд¿»¯Tϸ°ûµÄ·½·¨,·Ö±ðÐðÊöÆäʵÑéÔ­ÀíºÍÖ÷Òª²Ù×÷²½Öè¡£ xP\s^]e  
-mO#HZIq  
5. ÆÀ¼Ûºìϸ°ûÉú³ÉËØ(EPO)¡¢¸ÉÈÅËØ(IFN)ºÍ¼¯Âä´Ì¼¤Òò×Ó(CSF)ÔÚÁÙ´²Ä³Ð©¼²²¡µÄÓ¦Óᣠ"M/c0`>C!i  
JSUD$|RiJ  
Èý. Ñ¡ÔñÎÊ´ðÌâ(ÿÌâ10·Ö,¹²20·Ö¡£Çë°´±¨¿¼×¨Òµ´ðÌâ,Èç´ð·Ç±¾×¨ÒµÌâ»ò¶à´ðÌâ¾ùÊÓΪÎÞЧ¡£) @|A!?}  
>/-H!jUF]  
ÃâÒßѧרҵ£º t av@a)  
f r~Eb'8  
1. ÊÔÊöϸ°ûÒò×ÓÊÜÌåÖÐ,Ig³¬¼Ò×å¡¢ÔìѪÒò×ÓÊÜÌ峬¼Ò×å¡¢Éñ¾­Éú³¤Òò×ÓÊÜÌ峬¼Ò×åÒÔ¼°Ç÷»¯Òò×ÓÊÜÌ峬¼Ò×åµÄÖ÷Òª½á¹¹Ìصã,ÿ¸ö³¬¼Ò×åÀý¾Ù³ö2¸ö³ÉÔ±¡£ 2)IM<rf'^  
|&K;*g|a  
2. ÊԱȽÏÈËT¡¢BÁܰÍϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(±íÃæ±ê¼Ç)µÄÒìͬµã,ËüÃÇ·Ö±ð²ÎÓëÄÄЩÖ÷ÒªµÄÃâÒß¹¦ÄÜ? :2j`NyLI.  
DOyO`TJi  
´«È¾²¡Ñ§×¨Òµ£º I'xc$f_+  
WWSycH ?[  
1. ÈËÀàÃâÒßȱÏݲ¡¶¾(HIV)¸ÐȾÈËÌåºó,ÃâÒß¹¦Äܿɷ¢ÉúÄÄЩÖ÷ÒªµÄ±ä»¯?»úÀíÊÇʲô?ÈçºÎ½øÐÐÏàÓ¦µÄÃâÒßѧ¹¦Äܼì²â£¿ L9)gN.#  
"6C a{n1hk  
2. ÇëÆÀÊöÉö×ÛºÏÕ÷³öѪÈȲ¡¶¾(HFRSV)¸ÐȾºó»úÌåÃâÒßѧ±ä»¯µÄÓ벡ÀíËðÉ˵ĹØÏµ¡£ 2Pb+/1*ix  
>r`O@`^U  
Ïû»¯×¨Òµ£º 4- QlIIf  
 +C\79,r  
1.ÊÔÊöÓëÏû»¯ÏµÍ³ÓйصÄÖ×ÁöÏà¹Ø¿¹Ô­Ñо¿µÄ½øÕ¹¡£ (+gTIcc >  
}@LIb<Y  
2.¼òÊöճĤÏà¹ØÁܰÍÑù×éÖ¯(mucosal assiociated lymphoid tissue,MALT)µÄ×é³ÉºÍ¹¦ÄÜÌØµã¡£·ÖÃÚÐÍIgAÊÇÈçºÎ½øÐкϳɺͷÖÃÚµÄ? Xr^ 5Th\  
qGq]E `O  
µÚËľüÒ½´óѧһ¾Å¾ÅÁùÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ÃâÒßѧÊÔÌâ ?5't1219  
qt.4dTd:_  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© qJF'KHyU{l  
t{UVX%b  
1. Fas(CD95)/FasL e!0xh  
X8v)yDtw  
2. common chain of cytokine receptor r1F5'?NZ(0  
@5&57R3>  
3 . TCR/CD3 complex 2Bi]t%<{  
^XeJZkLEB  
4. negaive selection of thymocytes ,eTdQI;   
Fep@VkN  
5. artificial active immune n<|8Onw  
+|;Ri68  
6. anti-idiotypic !^Ay !  
2F dwX ,O.  
7. IgSF  DEu0Z  
?VxQ&^|  
8. Integrin gLSI?  
ug{sQyLN  
9. chemokine 1c/<2xO~  
mx1Bk9h%Xe  
10. B7/CD28 5O~xj:  
Y,mo}X<>  
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²60·Ö£© tag)IWAiE  
o9ys$vXt*  
1. ±È½ÏMHC¢ñºÍMHC¢òÀ࿹ԭ²ÎÓëµÄ¼Ó¹¤Ìá³Ê¿¹Ô­µÄ¹ý³Ì¡£ % iPIgma  
!<h9XccN  
2. ±È½ÏCTLºÍNKɱÉ˰Ðϸ°ûʱʶ±ðºÍɱÉË»úÖÆµÄÌØµã¡£ >g+Y//Z  
dC4`xUv  
3. ±È½ÏÃâÒßѧ¼ì²â·¨ºÍÉúÎïѧ»îÐÔ¼ì²â·¨¼ì²âϸ°ûÒò×ÓµÄÓÅȱµã¡£ P5dD&  
,]qc#KDq-1  
4. ·¢ÏÖÒ»ÖÖеİ×ϸ°û·Ö»¯¿¹Ô­»òÖ×ÁöÏà¹Ø¿¹Ô­,²¢ÖƱ¸Á˵¥¿Ë¡¿¹Ìå,ÊÔÉè¼ÆÊµÑé·½°¸¿Ë¡´Ë»ùÒò¡£ rY &lx}  
8>|4iT  
5. Ñ¡ÔñÏÂÊöÖÐÒ»¸öרÌâ,ÐðÊöÎÒ¹úÔÚÕâÒ»Ñо¿ÁìÓòµÄÏÖ×´¼°ÃæÁÙµÄÌôÕ½1)Ö×ÁöÃâÒߣ»(2)»ùÒòÖÎÁÆ£»(3)CD¿¹Ô­¡£ >f9Q&c$R  
,: z]15fX  
µÚËľüÒ½´óѧһ¾Å¾ÅÆßÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÃâÒßѧÊÔÌâ mGwJ>'+d  
k,OxGG  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© U1yspHiZ  
i5WO)9Us  
1. B7/CD28 -Nz OX"V]3  
@VND}{j  
2. Th1 subset g C8 deC8  
[$>@f{:  
3. seven predicated transmembrane domain receptor superfamily£¨STR superfamily£© Rc@lGq9  
blG?("0!  
4. antibody affinity maturation 4 q % Gc  
z {NK(oW  
5. AP-1 D!)h92CIDm  
%0u5d$bq  
6. single chain variable fragment£¨ScFv£© <X5V]f  
q`|E9  
7. NK cell receptor ! }eq~3  
925T#%y  
8. Zinkernagel-Doherty phenomenon .(Z^}  
 Cb|R  
9. Ig fold ARJtE@s6Y  
ye {y[$#3  
10. CD40/CD40L '7]9q#{su  
v49 i.c9  
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²36·Ö£© I=E\=UTG,5  
MA 6uJT  
1. ÊÔÊöÐØÏÙ΢»·¾³¶ÔÐØÏÙϸ°ûµÄÑ¡Ôñ×÷Óü°ÆäÓëTϸ°û¹¦ÄÜÐÔÑÇȺÐγɵĹØÏµ¡£ t/]za4w/  
"LZv\c~v,%  
2. ÊÔÊöÌåÒºÃâÒßÓ¦´ðµÄ¹æÂÉ£¬»ØÒä·´Ó¦ºÍ¿¹ÌåÀà±ðת»»µÄ»úÖÆÊÇʲô£¿ LKud'  
,+5 !1>\  
3. ÊԴӽṹºÍ¹¦ÄܵȽǶȣ¬²ûÊö°×ϸ°û·Ö»¯¿¹Ô­£¨CD£©¡¢Õ³¸½·Ö×Ó£¨integrin£©ºÍÃâÒßÇòµ°°×³¬¼Ò×壨IgSF£©ÈýÀà·Ö×ÓµÄÏ໥¹ØÏµ¡£Ä¿Ç°ÔÚÕâÒ»ÁìÓòÖÐÖ÷ÒªÑо¿ÈȵãÊÇʲô£¿ {X\FS   
O4W 2X@  
Èý. ÎÊ´ðÌ⣨24·Ö£¬µÚ1ÌâΪÃâÒßѧרҵ¿¼ÉúÊÔÌ⣬µÚ2ÌâΪѪҺ²¡Ñ§¿Æ¿¼ÉúÊÔÌ⣬µÚ3ÌâΪÏû»¯ÄÚ¿Æ¿¼ÉúÊÔÌ⣬ֻÔÊÐí´ð±¾×¨ÒµÊÔÌ⣩ h9%.tGx  
5)4?i p  
1. ÊԱȽÏTCRºÍBCR½á¹¹¼°Æäʶ±ð¿¹Ô­¡¢ÁܰÍϸ°û»î»¯ÐźŵķÖ×Ó»úÀí¡££¨ÃâÒßѧרҵ£©¡£ 0w$1Yx~C  
@^Kw\s  
2. ÊÔÊö°×Ѫ²¡ÃâÒßѧ·ÖÐÍÀíÂۺͷ½·¨µÄÑо¿½øÕ¹¡££¨ÑªÒº²¡Ñ§×¨Òµ£©¡£ [!#;QQ&M  
BQ~\p\  
3. ÊÔÊöÖ×ÁöÒßÃçµÄÑо¿½øÕ¹¡££¨Ïû»¯ÄÚ¿Æ×¨Òµ£©¡£ ;Ac!"_N?7  
$O9#4A;  
Ò»¾Å¾Å°ËÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ £¨ÃâÒßѧרҵºÍרҵ»ù´¡£© !;U}ax;AF  
WZ@$bf}f0  
Ò».Ãû´Ê½âÊÍ£¨Ã¿Ìâ3·Ö£¬¹²45·Ö£© C:}"?tri  
];Bk|xJ/>  
1.Co-stimulators (or co-stimulating molecules) hTAZGV(  
wo) lkovd  
2.NK-kB U$IB_a2  
rdm&YM`J  
3.Immunoglobulin superfamily eOd'i{f@F  
~,84E [VV  
4.antigen-presenting cell (APC) 9C1\?)"D^e  
i"y @Aj!7  
5.death domain j{NcDe pLn  
^{+_PWn  
6.CCR and CXCR Mg {=(No  
:\G`}_db'  
7.Lectin (or mitogen) p w`YMk  
>VvA&p71b  
8.Clusters of differentiation, CD) &B ^LaRg  
E$E #c8I:  
9.B7 family 69{q*qCW  
A]s|"Pav,  
10.Cytotoxic T lymphocyte, CTL) sxU 0Fg   
(wZ/I(4  
11.IL-15 and IL-15 receptor (IL-15R) |Skhx9};  
Zm/I&  
12.MHC restriction Vqxxm&^P  
@L5s.]vg=  
13.Affinity-chromatography E(Y}*.\]#s  
W v!%'IB  
14.Cyctosprin A, CsA 96S#Q*6+R  
!"QvV6Lq\  
15.Antibody-dependent cell-mediated cytotoxicity, ADCC) aO$I|!tl  
c R6:AGr  
¶þ.ÎÊ´ðÌ⣨ÿÌâ10·Ö£¬¹²30·Ö£© {:c5/ ,7c;  
ppK`7J>Z  
1.ºÎΪTh1ºÍ Th2ÑÇȺ£¿ÈçºÎ¼ì²â£¿ÔÚÁÙ´²ÉÏÓкÎÒâÒ壿 jkfc=O6^  
Y4I;-&d's  
2.ÊÔÊöÃâÒßÇòµ°°×£¨Ig£©µÄ½á¹¹Ó빦ÄܵĹØÏµ¡£ (od9adSehV  
6 ly`lu9  
3.ÊԱȽÏTϸ°ûÊÜÌ壨TCR/CD3£©ÓëBϸ°ûÊÜÌ壨BCR£©µÄ×é³É¡¢½á¹¹¼°Æäʶ±ð ¿¹Ô­µÄÌØµã¡£ *32hIiCm  
x3Ze\N8w  
Èý.Ñ¡ÔñÎÊ´ðÌ⣨¸÷רҵ¿¼ÉúÖ»´ðÒ»µÀ±¾×¨ÒµÊÔÌ⣬25·Ö£© `0Bk@B[>  
NNP u t$.  
ÃâÒßѧרҵ£º J>p6')Y6~  
8zzY;3^h;  
1.ÊÔÊöB7/CD28, CTLA-4£¬CD40/CD40L£¬LFA-1/ICAM-1£¬CD2/LFA-3µÄ½á¹¹¡¢·Ö²¼ÒÔ¼°Ï໥×÷Óúó½éµ¼µÄÖ÷ÒªÉúÎïѧ¹¦ÄÜ¡£ 2*ByVK  
~l"]J'jF"H  
Ïû»¯ÄÚ¿Æ£º 2.Ö×Áö¿¹Ô­·ÖΪÄļ¸Àࣿ»úÌ忹Ö×ÁöÃâÒßÖ÷ÒªÓÐÄÄЩÒòËØ£¨»úÖÆ£©£¿¼òÊöÌá¸ß¿¹Ö×ÁöÃâÒßÑо¿µÄÂԲߡ£ sA!$}W  
fm1yZX?`  
ѪҺ²¡Ñ§×¨Òµ£º 3.ºÎΪ°×Ѫ²¡µÄÃâÒßѧ·ÖÐÍ£¿ºÎÎªÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£©£¿GVHR·¢ÉúµÄÖ÷ÒªÔ­Òò£¨Ìõ¼þ£©ÊÇʲô£¿ {Etvu  
AS'%Md&I  
Ò»¾Å¾ÅÄê¾Å²©Ê¿ÉúÈëѧ¿¼ÊÔÊÔÌâ (רҵ»ù´¡: ÃâÒßѧ) `A ^  
fv/Nf "  
Ò».Ãû´Ê½âÊÍ(ÿÌâ5·Ö,¹²45·Ö) 4Be'w`Q {  
Yh2[ nF_  
1. ADCC(antibody dependent cell-mediated cytotoxicity) omzG/)M:O  
Zi= /w  
2. »·æß¾úËØ(cyclosporin) t4v@d  
liU8OXBl  
3. KIR(killer cell inhibitory receptor) y,s`[=CT  
,9Si 3vn  
4. HLDA(human leucocyte differentiation antigen) %8{nuq+c  
Gy )2  
5. Interleukin 18(IL-18) }\0ei(%H  
O+OU cMa,  
6. ÕûºÏËØ(integrin) V@rqC[on  
5y8VA4L/o  
7. Fas/FasL @L$!hTaP  
L@s_)?x0  
8. FcR(ÃâÒßÇòµ°°×Fc¶ÎÊÜÌå) L Iz<fB  
T:Nc^QP|tm  
9. ϸ°û¼äÕ³¸½·Ö×Ó(ICAM) /V GI@"^v  
ny1;]_X_  
10. Th1/Th2 )M><09  
`vZX"+BAh  
11. »ùÒòÒßÃç(DNAÒßÃç) U0Uy C  
-}_1f[b  
12. chemokines and chemokine receptor _ee<i8_Va  
T~L&c  
13. ÃâÒßÄÍÊÜ CEW1T_1U<\  
P; h8  
14. ¹²´Ì¼¤·Ö×Ó pX+4B=*  
Wdi`Z E  
15. ËÀÍö½á¹¹Óò(death domain) # %EHcgF  
u'nQC*iJb  
¶þ.ÎÊ´ðÌâ(µÚ1¡¢2Ìâ¸÷18·Ö,µÚ3Ìâ19·Ö) J$5Vjh'aM  
t{s*,X\b  
1. ÊԱȽÏɱÉËÐÔTϸ°û(CTL)Óë×ÔȻɱÉËϸ°û(NK)ÔÚɱÉ˰Ðϸ°û¹ý³ÌÖÐ,ʶ±ðϸ°û¶¾¼°½éµ¼ÃâÒß¹¦ÄÜÓкβ»Í¬? eR0$CTSw  
#_{Q&QUk  
2. 70Äê´úÒÔÀ´,ÓйØIgºÍÌåÒºÃâÒßÑо¿´æÔÚÒÔϼ¸ÏîÖØ´ó·¢ÏÖºÍÍ»ÆÆ¶ø»ñµÃҽѧºÍÉúÎïѧŵ±´¶û½±,Çë·Ö±ð²ûÊöËüÃǵÄÀíÂÛÒâÒå¼°ÔÚҽѧʵ¼ùÖеÄÓ¦Óᣠ*YSRZvD<\  
/3&MUB*z&y  
£¨1£©1972Ä꣺θµ°°×øºÍľ¹Ïµ°°×øˮ½âIg£¬»ñµÃFab¡¢Fc¡¢F£¨ab¡¯£©2µÈƬ¶Î \W]gy_=D{  
YS_3Cq  
£¨2£©1977Ä꣺·ÅÉäÃâÒß·¨ -We9 FO~  
A,BYi$  
£¨3£©1984Ä꣺ÁܰÍϸ°ûÔÓ½»ÁöºÍµ¥¿Ë¡¿¹Ìå uFha N\S  
QFMA y>Gdn  
£¨4£©1987Äê: Ig»ùÒòµÄ½á¹¹ 3. ½üÄêÀ´ÔÚÖ×ÁöÃâÒßÑо¿ÁìÓòÖÐÓÐÄÄÐ©ÖØÒª½øÕ¹?ÊÔÊöµ±Ç°Ìá¸ß»úÌ忹Ö×ÁöÃâÒßµÄÖ÷Òª²ßÂÔ¡£ z;!"i~fFK  
}B a_epM  
Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(ÃâÒßѧרҵ) ÎÊ´ðÌâ(ÿÌâ25·Ö) &g PP# D6A  
Z"RgqNf  
1. ÊԱȽÏTϸ°ûÊÜÌ壨TCR£©¡¢Bϸ°ûÊÜÌ壨BCR£©ºÍNKϸ°ûÊÜÌ壨NKCR£©µÄ×é³É£¬Ê¶±ðÅäÌåÒÔ¼°ÐźÅתµ¼µÄÒìͬµã¡£ }opw_h+/F  
g/fpXO\  
2. ÒÔÐØÏÙÒÀÀµ¿¹Ô­´Ì¼¤»úÌå²úÉú¿¹ÌåµÄÃâÒßÓ¦´ðΪÀý£¬Tϸ°ûºÍBϸ°ûÊÇÈçºÎÏ໥×÷Óã¿ÓÐÄÄЩճ¸½·Ö×Ӻ͹²´Ì¼¤·Ö×Ó²ÎÓëT¡¢Bϸ°ûµÄÏ໥×÷Óã¿ s8)`wH ?  
2 rr=FJ  
3. Éö×ÛºÏÕ÷³öѪÈÈ(HFRS)²¡¶¾µÄ½á¹¹»ùÒòÒѾ­¸ãÇå³þ,ΪÁË֤ʵHFRS²¡¶¾¸ÐȾ»úÌå(ÒÔBalb/CСÊóΪÀý)¿É²úÉúHFRS²¡¶¾ºËÒ¿ǵ°°×(NP)ÌØÒìÐÔCTL,²¢ÔÚÃâÒß·À»¤ÖÐÆðÖØÒª×÷ÓÃ,ÇëÓ¦ÓÃÃâÒßѧÀíÂۺͷ½·¨,Éè¼ÆÒ»ÏµÍ³ÊµÑé,¼ÓÒÔ֤ʵ¡£ 4. Àý¾Ù¶þ¸ö½üÄêÀ´Ï¸°ûºÍ·Ö×ÓÃâÒßѧÑо¿ÖгöÏÖµÄеÄÈȵã,Çë·Ö±ðÆÀÊöÆäÑо¿ÒâÒå¡¢·¢Õ¹Ç÷ÊÆÒÔ¼°Ó¦ÓÃǰ¾°¡£
ÆÀ¼ÛÒ»ÏÂÄãä¯ÀÀ´ËÌû×ӵĸÐÊÜ

¾«²Ê

¸Ð¶¯

¸ãЦ

¿ªÐÄ

·ßÅ­

ÎÞÁÄ

¹àË®

  
ÃèÊö
¿ìËٻظ´

ÑéÖ¤ÎÊÌâ:
2+6=? ÕýÈ·´ð°¸:8
°´"Ctrl+Enter"Ö±½ÓÌá½»